Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491602 | SCV000580458 | pathogenic | Hereditary cancer-predisposing syndrome | 2015-02-06 | criteria provided, single submitter | clinical testing | The c.2520_2521delAAinsT pathogenic mutation, located in coding exon 15 of the MSH2 gene, results from the deletion of two nucleotides and insertion of one nucleotide causing a translational frameshift with a predicted alternate stop codon. Since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Gene |
RCV000657835 | SCV000779591 | pathogenic | not provided | 2017-12-15 | criteria provided, single submitter | clinical testing | This deletion of two nucleotides is denoted MSH2 c.2520_2521delAAinsT at the cDNA level and p.Ile841Ter (I841X) at the protein level. The normal sequence, with the bases that are deleted and inserted in brackets, is ATGT[delAA][insT]TAGA. The combined insertion and deletion creates a nonsense variant, which changes an Isoleucine to a premature stop codon (ATA>TAG). Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider MSH2 c.2520_2521delAAinsT to be pathogenic. |